When Eye Injections Alone Aren’t Enough: Adding a Steroid Implant for Diabetic Macular Edema
Adding a Steroid Implant to Your Plan at a Glance
Call your eye doctor the same day if any of these start after an implant. Go to an emergency room if you cannot reach the office.
- Severe eye pain, or an ache that keeps building
- A red and painful eye, or new light sensitivity
- Decreased vision, halos around lights, or a shower of new floaters
The implant's drug label tells patients to report any sign of infection inside the eye without delay, and it warns that these injections have been linked to infection, inflammation, raised eye pressure, and retinal detachment1. Both problems are treatable when caught early. Infection is rare: in a large study of anti-VEGF eye injections it occurred about once in every 2,857 injections2. Raised pressure is usually manageable too: across the three-year dexamethasone implant trials, increases in eye pressure were usually controlled with medicine or with no treatment at all3. Calling the same day keeps a treatable problem small.
A steroid implant is what your doctor reaches for when anti-VEGF injections are not drying your macula enough, when the effect fades too fast between visits, or when coming in for frequent injections is not workable for you. A specialist review describes steroids as mainly used only when anti-VEGF treatment either dries out the macula inadequately or wears off too quickly, or when frequent injections are prohibitive for the patient4. It is not an upgrade and not a last resort. It works on swelling by a different route, and lasts far longer per dose. It also carries trade-offs that anti-VEGF does not.
It is a tiny drug pellet placed inside the eye, not a pill and not a drop. The pellet sits in the vitreous, the clear gel filling the eye, and releases a small dose of corticosteroid steadily over months or years. Medicines called steroids can help with swelling in the retina5. Delivering it inside the eye puts the drug where the swelling is, and the amount involved is measured in fractions of a milligram.
You are the typical candidate if you have had several anti-VEGF injections and your scans still show fluid, or the fluid returns within weeks every time. Guidelines put anti-VEGF first for center-involved swelling with vision loss and list corticosteroids among the add-on treatments that may be considered6. People who have already had cataract surgery, and people who cannot get to monthly appointments, tend to fit this step best.
The Two Steroid Implants and How They Differ
Macular edema happens when blood vessels leak into the part of the retina called the macula, and when diabetic retinopathy causes that swelling it is called diabetic macular edema5. Inflammation is a large part of why those vessels keep leaking. Anti-VEGF medicines block one leak signal. Steroids work further upstream, damping the broader inflammation that drives fluid into the macula. That is why a steroid can help an eye that anti-VEGF alone has not dried out. It is also why the side effects are different, because a steroid inside the eye affects the lens and the drainage system too.
This is the shorter-acting of the two and the more common starting point. It is a dexamethasone 0.7 mg pellet in a dissolving polymer, labeled for diabetic macular edema1. In practice it works for roughly 3 to 4 months before it needs repeating4. Because the pellet dissolves on its own, nothing has to be removed later, and your doctor can stop simply by not repeating it.
This is the long-haul option, and it is deliberately harder to qualify for. It carries 0.19 mg of fluocinolone acetonide, releases about 0.25 micrograms a day, and lasts 36 months; its label is written for people already treated with a course of corticosteroids who did not have a clinically significant rise in eye pressure7. In other words, you usually have to pass a steroid pressure test before this one is offered.
| Implant | How long one dose works | Usually suits |
|---|---|---|
| Dexamethasone 0.7 mg | About 3 to 4 months | A first steroid trial; dissolves on its own |
| Fluocinolone 0.19 mg | Up to 36 months | Long-standing swelling, after a steroid trial with stable pressure |
When Doctors Add a Steroid to Anti-VEGF Injections
Persistent means the fluid is still there after a real trial of anti-VEGF, not after one or two doses. The trial that tested adding a steroid enrolled eyes still swollen after at least three anti-VEGF injections8, which is a fair marker of a real trial. Your doctor watches two things: the thickness number on your scan and your reading vision. If the scan improves but stalls above normal while your vision sits flat, that is the pattern that prompts a conversation about adding a steroid.
This is where honest expectations matter. In a randomized trial of 129 eyes still swollen after at least three anti-VEGF injections, adding a dexamethasone implant to continued ranibizumab gave a mean gain of 2.7 letters at 24 weeks versus 3.0 letters with the anti-VEGF alone, no meaningful difference, while the retina thinned considerably more (110 microns versus 62 microns); 29 of every 100 combination eyes had raised eye pressure or started pressure drops, versus none on anti-VEGF alone8. Drier scans did not equal better letters in that study.
Steroids inside the eye speed up cataract, so the calculation is different once your natural lens is gone. In the three-year dexamethasone implant trials, cataract-related events happened in 67.9 of every 100 eyes that still had their own lens, against 20.4 of every 100 on sham3. If you have an artificial lens already, that whole column of risk drops away, which is why many doctors offer a steroid earlier to people who are past cataract surgery.
Other moves often come first. Guidelines keep anti-VEGF as the initial choice and describe focal laser as a possible next step for edema that persists6. Switching anti-VEGF medicines or extending the current trial are also reasonable before a steroid. If your eye pressure already runs high, or you have glaucoma, a steroid may not be offered at all. The point is that persistent fluid means change the plan, not that a steroid is the automatic next move.
How the Implant Is Given and What Follow-Up Looks Like
The visit looks much like an anti-VEGF injection visit, using a slightly wider applicator. Your eye is numbed with drops or gel and cleaned with antiseptic, a small holder keeps the lid open, and the pellet is placed through the white of the eye in a few seconds. Expect a gritty feeling and a red patch for a few days. Many people notice a small dark speck drifting in their vision, which is the pellet itself.
The rhythm depends on which implant you get. Over three years in the dexamethasone trials, patients received an average of 4.1 implants in total3. The fluocinolone insert is designed to run for 36 months from a single placement7. Many people continue anti-VEGF alongside, so a steroid does not always mean an end to the other injections.
This is the part that makes steroid treatment safe rather than risky. Your doctor will check eye pressure at intervals after the implant, typically within the first weeks and then regularly, because a steroid pressure rise is silent until it is advanced. Raised eye pressure is among the most common reactions to the dexamethasone implant, reported along with cataract and a red patch on the eye in 20 to 70 of every 100 patients1. Caught on a check, it is usually managed with drops.
Who Should Not Get a Steroid Implant
Some situations are firm barriers, not judgment calls. The dexamethasone implant is contraindicated in people with an active infection in or around the eye, in glaucoma in those who have a cup-to-disc ratio greater than 0.8, with a torn or ruptured posterior lens capsule, or with a known hypersensitivity to it1. The fluocinolone insert is likewise contraindicated in eye infections, in glaucoma with an optic nerve cup-to-disc ratio above 0.8, and in hypersensitivity7. Tell your doctor about any glaucoma history.
This one is specific and easy to miss. The thin membrane behind your lens normally keeps the pellet in the back of the eye. If that posterior capsule is torn or ruptured, the dexamethasone implant can migrate into the front chamber of the eye, which is why the label rules it out1. If you have had complicated cataract surgery, a capsule tear, or certain lens implants, say so before the appointment rather than on the day.
Some people are steroid responders, meaning their eye pressure climbs whenever they are given corticosteroids. In the studies behind the dexamethasone implant's label, about 42 of every 100 patients given the implant used some pressure-lowering medicine, against about 10 of every 100 given a sham procedure1. That is why the long-acting fluocinolone insert is labeled only for people already given a course of corticosteroids who did not have a clinically significant pressure rise7. A shorter-acting steroid is the practical way to find out. If your pressure behaves, the three-year option opens up. If it does not, you have learned that safely.
Side Effects: What Is Common and What Is Serious
If you still have your natural lens, expect this one rather than hope to avoid it. With the fluocinolone insert, cataract occurred in 82 of every 100 treated patients versus 50 of every 100 on sham7. Corticosteroids in the eye may produce posterior subcapsular cataract, raised pressure, and glaucoma1. Cataract surgery is the routine way to deal with it, so for many people this is an accepted cost rather than a reason to decline.
Pressure is the risk that needs monitoring rather than acceptance. In the studies behind the dexamethasone implant's label, a pressure rise of 10 mmHg or more at some visit happened in about 28 of every 100 patients given the implant versus about 4 of every 100 given a sham procedure, about 42 of every 100 used a pressure-lowering medicine versus about 10 of every 100, and about 1 of every 100 needed a surgical step for raised pressure1. In the three-year trials, pressure rises were usually controlled with medicine or with no treatment at all, and about 0.6 of every 100 patients on the 0.7 mg implant needed a drainage operation (clinical: trabeculectomy)3. With the fluocinolone insert, incisional glaucoma surgery was needed by 3.7 of every 100 patients versus 0.5 of every 100 on sham9. Most cases are handled with drops alone.
These are uncommon, and they are the reason for the same-day rule. Intravitreal injections have been associated with infection inside the eye, inflammation, raised pressure, and retinal detachment1. In a large study of anti-VEGF eye injections, infection occurred about once in every 2,857 injections2. Treated promptly, many eyes do well. That is the whole argument for calling rather than waiting to see whether it settles.
Not everything after an implant is a warning sign. A red patch on the white of the eye is a tiny broken vessel and generally clears over one to two weeks. A gritty or scratchy feeling for a day or so is typical, and artificial tears help. Seeing the implant as a small floating speck is expected and usually fades from notice. What does not belong on this list is worsening pain or dropping vision.
What to Expect Over the Next Few Years
Population figures are not a personal forecast, and your own result may differ. Over three years, 22.2 of every 100 patients on the 0.7 mg dexamethasone implant gained 15 or more letters versus 12.0 of every 100 on sham3. With the low-dose fluocinolone insert, 28.7 of every 100 gained 15 or more letters at 24 months versus 16.2 of every 100 on sham9. For many people the realistic goal is holding the vision they have.
The gain that patients feel most is not always on the eye chart. Trading monthly injections for an implant that runs for months, or for three years, can hand back a large amount of time, travel, and worry. That matters most if you drive a long way to clinic, depend on someone else for rides, or cannot take repeated time off work. Discuss this openly, because visit burden is a legitimate reason to change the plan.
Steroid implants generally cost more per dose than the least expensive anti-VEGF option, and many plans require documentation that anti-VEGF was tried first. Coverage rules differ between Medicare and commercial plans. Ask the practice for a benefits check before the appointment is booked, and ask whether a manufacturer assistance program applies. Sorting this out early avoids a gap in treatment later.
When to Call Your Retina Doctor
Treat the first days after an implant as a watch period. Call the same day for eye pain that keeps building, a red eye that becomes painful, new sensitivity to light, a clear drop in vision, or halos around lights. The label names eye pain, redness, light sensitivity, and blurred vision as the symptoms to report without delay1. None of these mean the implant has failed. They mean something needs checking now rather than at your next visit.
Some changes are less urgent but should not wait for the next scheduled slot. Report reading vision that has slipped, straight lines that look newly bent, a new dull patch in the center, or glare that is getting harder to tolerate at night. Growing glare often signals cataract rather than anything dangerous, and it is a solvable problem. Call if you are going to miss an appointment, so the pressure checks can be rescheduled.
Follow-up is not optional with a steroid on board. People with diabetes should have a comprehensive dilated eye exam at least once a year, and those with diabetic retinopathy may need exams as often as every 2 to 4 months10. On top of that, your retina doctor will set pressure checks around each implant. Keeping those is what lets a steroid be used confidently rather than cautiously.
Questions People Ask About Steroid Implants for Macular Swelling
Usually not entirely. Many people continue anti-VEGF alongside the implant, and the steroid is added to handle fluid the anti-VEGF is not clearing. The trial that tested this combination kept patients on continued ranibizumab and added the dexamethasone implant on top8. Some people do end up on the implant alone, particularly with the three-year insert. Ask your doctor which pattern they are aiming for in your eye.
No one can promise that, and the trial data explain why. Adding a dexamethasone implant to anti-VEGF in eyes with persistent swelling thinned the retina considerably more but did not improve letters read at 24 weeks8. A drier macula is worth having, and for some eyes it does convert into better vision over time. Going in with the goal of protecting vision rather than gaining letters is the more realistic frame.
If you still have your own lens, it is likely rather than possible. Cataract occurred in 82 of every 100 patients given the fluocinolone insert, against 50 of every 100 on sham7. Cataract surgery is the standard way to address a steroid-related cataract, and many people plan for it as a scheduled step rather than an unwelcome surprise.
It is usually managed, not a reason to panic. In the studies behind the implant's label, about 42 of every 100 patients used a pressure-lowering medicine, while about 1 of every 100 needed a surgical step for raised pressure1. Across the three-year trials, these pressure rises were usually controlled with medicine or with no treatment at all3. Drops handle the large majority. Laser or surgery is reserved for the small group that drops cannot control. This is exactly why the pressure checks are scheduled rather than optional.
Not easily, and that is worth understanding before you consent. The dexamethasone pellet dissolves on its own over months, so stopping means simply not repeating it. The fluocinolone insert is non-dissolving and designed to release drug for 36 months7. Removing one is possible but is a surgical undertaking and rarely done. Choose the shorter-acting option first if you want the ability to change course.
Swelling usually starts responding within weeks rather than days, and your scan will show it before you feel it. Vision often lags the anatomy, sometimes by months, because a macula that has been wet for a long time needs time to recover. Do not judge the decision on the first two weeks. Your doctor will compare scans across visits, which is a far more reliable signal than day-to-day vision.
More Questions About Living With a Steroid Implant
The dose is small and released slowly inside the eye rather than taken by mouth. The fluocinolone insert, for example, releases about 0.25 micrograms a day7, and the risks its label highlights are local ones in the eye. Still, tell your diabetes team about any eye treatment you start. If you notice unexplained changes in your blood sugar readings after an implant, report them to both teams rather than assuming they are unrelated.
Yes, if both eyes need it, though many doctors treat one eye first. Staggering lets your team see how your pressure responds before committing the second eye, which is useful given that some people are steroid responders. If both eyes are treated at one visit, practices use separate sterile instruments and separate drug lots for each eye. Ask which approach your practice prefers.
No. It controls the swelling and inflammation, but the damaged retinal vessels remain, which is why fluid can return once the drug runs out. Managing your diabetes helps prevent or delay vision loss10. Blood sugar, blood pressure, and cholesterol control still do real work here. Treat the implant as one part of a plan rather than the whole of it.
- How many anti-VEGF injections have I had, and what did each scan show afterward?
- Which implant are you recommending for me, and why that one first?
- Do I still have my natural lens, and how does that change the risk for me?
- What is my eye pressure now, and how often will you check it after the implant?
- Will I keep having anti-VEGF injections alongside the implant?
- What result at three months would make you repeat it, and what would make you stop?
- Who do I call after hours if I get pain, halos, or falling vision?
- US Food and Drug Administration label via DailyMed (2024). OZURDEX (dexamethasone intravitreal implant) 0.7 mg: US prescribing information.
- Ophthalmology (2024). Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections.
- Boyer DS, et al. Ophthalmology (2014). Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients With Diabetic Macular Edema (MEAD).
- EyeNet Magazine, American Academy of Ophthalmology (2023). Diabetic Macular Edema: Personalizing Treatment.
- National Eye Institute (NIH) (2025). Macular Edema.
- American Academy of Ophthalmology (2025). Diabetic Retinopathy Preferred Practice Pattern (2025).
- US Food and Drug Administration label via DailyMed (2025). ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg: US prescribing information.
- Maturi RK, et al. JAMA Ophthalmology (2018). Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial (Protocol U).
- Campochiaro PA, et al. Ophthalmology (2011). Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients With Diabetic Macular Edema (FAME, 24-month report).
- National Eye Institute (NIH) (2025). Diabetic Retinopathy.